A World Without
Infectious Disease
Approximately 300 million people worldwide live with chronic hepatitis B and hepatitis Delta, the most severe form of viral hepatitis, co-infects 12 million people globally.
Vir is proud to be in the fight against chronic hepatitis B (HBV) and hepatitis Delta (HDV), and is committed to advancing research and therapies aimed at a functional cure for both diseases. We hope our efforts help accelerate the World Health Organization’s target of eradicating viral hepatitis by 2030.
Learn more about our ongoing clinical programs here.
Global Impact
Infectious diseases are among the leading causes of death worldwide.
Vir is focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
A new era
Remarkable advances have improved our understanding of pathogens and the immune system.
Our four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes.
To prevent, treat, and cure
We are taking aim at some of the world’s largest and most serious infectious diseases, infections that are evasive, challenging, or insufficiently addressed by current approaches including COVID-19, hepatitis B, influenza A and HIV.